无菌肿瘤骨再植重建对骨干骨肉瘤存活有好处吗?

Q2 Medicine Sarcoma Pub Date : 2020-01-19 eCollection Date: 2020-01-01 DOI:10.1155/2020/4092790
Prakash Nayak, Ashish Gulia, Ajay Puri
{"title":"无菌肿瘤骨再植重建对骨干骨肉瘤存活有好处吗?","authors":"Prakash Nayak,&nbsp;Ashish Gulia,&nbsp;Ajay Puri","doi":"10.1155/2020/4092790","DOIUrl":null,"url":null,"abstract":"<p><p>Does reimplantation of sterilized tumor bone for reconstruction provide outcome benefits in intercalary osteosarcoma based on the potential immunogenic effect of reimplanted sterilized tumor tissue? Of 720 cases of surgically treated high-grade osteosarcoma patients treated at our institute from 2006 to 2013, 61 had predominantly diaphyseal disease. All patients were nonmetastatic at presentation. Patient and tumor characteristics, treatment details, and local recurrence-free, metastasis-free, and overall survival were compared for 24 patients who had reconstruction with sterilized tumor bone reimplantation vs 37 who did not. Both the groups were well matched in terms of baseline characteristics. Means were compared with the <i>t</i>-test, proportions with the chi-square test, and survival with the log-rank test. The Kaplan-Meier method was used to construct time to event curves. Cox proportional hazard regression modeling was employed for multivariate time to event analysis. Twenty-two had extracorporeal radiation and reimplantation (ECRT) with or without the vascularised fibula. Fifty-gray single dose was used in all cases. Two had pasteurization and reimplantation. Thirty seven had non-reimplantation reconstructions (including intercalary or osteoarticular endoprosthesis, pedicled bone grafts, rotation-plasty, and amputations). Five-year local recurrence-free survival was 85% for reimplantation and 97% for non-reimplantation groups (<i>p</i>=0.17). Five-year metastasis-free survival was 63% and 54%, respectively (<i>p</i>=0.44). Five-year overall survival was 70% and 58%, respectively (<i>p</i>=0.39). The data from this study did not demonstrate significantly better local recurrence-free, distant relapse-free, or overall survival benefit in the tumor bone reimplantation group.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"4092790"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/4092790","citationCount":"1","resultStr":"{\"title\":\"Does Reconstruction with Reimplantation of Sterilized Tumor Bone Provide Survival Benefit in Diaphyseal Osteosarcoma?\",\"authors\":\"Prakash Nayak,&nbsp;Ashish Gulia,&nbsp;Ajay Puri\",\"doi\":\"10.1155/2020/4092790\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Does reimplantation of sterilized tumor bone for reconstruction provide outcome benefits in intercalary osteosarcoma based on the potential immunogenic effect of reimplanted sterilized tumor tissue? Of 720 cases of surgically treated high-grade osteosarcoma patients treated at our institute from 2006 to 2013, 61 had predominantly diaphyseal disease. All patients were nonmetastatic at presentation. Patient and tumor characteristics, treatment details, and local recurrence-free, metastasis-free, and overall survival were compared for 24 patients who had reconstruction with sterilized tumor bone reimplantation vs 37 who did not. Both the groups were well matched in terms of baseline characteristics. Means were compared with the <i>t</i>-test, proportions with the chi-square test, and survival with the log-rank test. The Kaplan-Meier method was used to construct time to event curves. Cox proportional hazard regression modeling was employed for multivariate time to event analysis. Twenty-two had extracorporeal radiation and reimplantation (ECRT) with or without the vascularised fibula. Fifty-gray single dose was used in all cases. Two had pasteurization and reimplantation. Thirty seven had non-reimplantation reconstructions (including intercalary or osteoarticular endoprosthesis, pedicled bone grafts, rotation-plasty, and amputations). Five-year local recurrence-free survival was 85% for reimplantation and 97% for non-reimplantation groups (<i>p</i>=0.17). Five-year metastasis-free survival was 63% and 54%, respectively (<i>p</i>=0.44). Five-year overall survival was 70% and 58%, respectively (<i>p</i>=0.39). The data from this study did not demonstrate significantly better local recurrence-free, distant relapse-free, or overall survival benefit in the tumor bone reimplantation group.</p>\",\"PeriodicalId\":21431,\"journal\":{\"name\":\"Sarcoma\",\"volume\":\"2020 \",\"pages\":\"4092790\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2020/4092790\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sarcoma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2020/4092790\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/4092790","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

基于移植的灭菌肿瘤组织的潜在免疫原性作用,移植灭菌肿瘤骨进行重建是否能为骨间骨肉瘤提供预后益处?在我院2006 - 2013年手术治疗的720例高级别骨肉瘤患者中,61例以骨干病变为主。所有患者在就诊时均无转移。我们比较了24例无菌骨重建患者和37例未消毒骨重建患者的患者和肿瘤特征、治疗细节、局部无复发、无转移和总生存率。两组在基线特征方面都很匹配。均值比较采用t检验,比例比较采用卡方检验,生存比较采用log-rank检验。Kaplan-Meier方法用于构造时间到事件曲线。采用Cox比例风险回归模型进行多变量时间-事件分析。22例接受体外放射线和再植入术(ECRT),带或不带带血管的腓骨。所有病例均采用50灰单剂量。其中两例进行了巴氏消毒和再植。37例非再植重建(包括骨间或骨关节内假体、带蒂骨移植物、旋转成形术和截肢)。再植组5年局部无复发生存率为85%,非再植组为97% (p=0.17)。5年无转移生存率分别为63%和54% (p=0.44)。5年总生存率分别为70%和58% (p=0.39)。本研究的数据并没有显示肿瘤骨再植组有更好的局部无复发、远端无复发或总体生存获益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Does Reconstruction with Reimplantation of Sterilized Tumor Bone Provide Survival Benefit in Diaphyseal Osteosarcoma?

Does reimplantation of sterilized tumor bone for reconstruction provide outcome benefits in intercalary osteosarcoma based on the potential immunogenic effect of reimplanted sterilized tumor tissue? Of 720 cases of surgically treated high-grade osteosarcoma patients treated at our institute from 2006 to 2013, 61 had predominantly diaphyseal disease. All patients were nonmetastatic at presentation. Patient and tumor characteristics, treatment details, and local recurrence-free, metastasis-free, and overall survival were compared for 24 patients who had reconstruction with sterilized tumor bone reimplantation vs 37 who did not. Both the groups were well matched in terms of baseline characteristics. Means were compared with the t-test, proportions with the chi-square test, and survival with the log-rank test. The Kaplan-Meier method was used to construct time to event curves. Cox proportional hazard regression modeling was employed for multivariate time to event analysis. Twenty-two had extracorporeal radiation and reimplantation (ECRT) with or without the vascularised fibula. Fifty-gray single dose was used in all cases. Two had pasteurization and reimplantation. Thirty seven had non-reimplantation reconstructions (including intercalary or osteoarticular endoprosthesis, pedicled bone grafts, rotation-plasty, and amputations). Five-year local recurrence-free survival was 85% for reimplantation and 97% for non-reimplantation groups (p=0.17). Five-year metastasis-free survival was 63% and 54%, respectively (p=0.44). Five-year overall survival was 70% and 58%, respectively (p=0.39). The data from this study did not demonstrate significantly better local recurrence-free, distant relapse-free, or overall survival benefit in the tumor bone reimplantation group.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Sarcoma
Sarcoma Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
5.00
自引率
0.00%
发文量
15
审稿时长
14 weeks
期刊介绍: Sarcoma is dedicated to publishing papers covering all aspects of connective tissue oncology research. It brings together work from scientists and clinicians carrying out a broad range of research in this field, including the basic sciences, molecular biology and pathology and the clinical sciences of epidemiology, surgery, radiotherapy and chemotherapy. High-quality papers concerning the entire range of bone and soft tissue sarcomas in both adults and children, including Kaposi"s sarcoma, are published as well as preclinical and animal studies. This journal provides a central forum for the description of advances in diagnosis, assessment and treatment of this rarely seen, but often mismanaged, group of patients.
期刊最新文献
Oral Etoposide for Relapsed or Refractory Ewing Sarcoma in Adolescent and Adult Patients. Incidence of Undifferentiated Pleomorphic Sarcoma (UPS) in the United States. Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients. ATRX and Its Prognostic Significance in Soft Tissue Sarcoma. Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1